INS and type 2 diabetes mellitus: Type 2 diabetes medications, specifically GLP-1 receptor agonists and DPP-4 inhibitors, can be effectively repurposed to treat Parkinson’s disease by targeting shared pathological mechanisms such as insulin resistance, neuroinflammation, oxidative stress, and ferroptosis, thereby providing neuroprotective effects and slowing disease progression.